Ipamorelin vs KPV
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →KPV
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.
Full details →Side-by-Side Comparison
| Aspect | Ipamorelin | KPV |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 200 mcg–500 mcg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 8–12 weeks | 4–8 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. | Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors. |
| Typical Dosage | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. | Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation. |
| Administration | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. | Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides. |
| Side Effects | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. | Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action. |
| Best For |
What They Have in Common
Ipamorelin, KPV are both commonly used for:
Key Differences
Unique to Ipamorelin:
Unique to KPV:
Which Has Stronger Evidence?
- Recovery & Healing: Ipamorelin has stronger research support.
| Goal | Ipamorelin | KPV |
|---|---|---|
| Recovery & Healing | medium | low |
Key Studies
Ipamorelin
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
Animal reproduction science, 2024
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
Physiology & behavior, 2024
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
International journal of colorectal disease, 2014
KPV
- KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling.
Tissue & cell, 2026
- KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.
Advanced healthcare materials, 2024
- A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.
Acta biomaterialia, 2022
Ready to Learn More?
Looking for trusted sources?